ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pediatric

Healthcare Professionals Can Tap the ARP for Assistance

From the College  |  August 1, 2019

The ARP has a lot to offer members, including training and professional development, patient resources and volunteer match opportunities.

Filed under:Career DevelopmentEducation & TrainingProfessional Topics Tagged with:Association of Rheumatology Professionals (ARP)EducationMember benefitsprofessional developmentThe Training RheumTraining

Ethics Forum: Beware Your Intellectual Conflicts of Interest

Evan Mulvihill, MD, MPH  |  July 18, 2019

A senior rheumatologist with extensive experience in the management of systemic lupus erythematosus is asked to help draft clinical guidelines for the treatment of lupus nephritis. Neither she nor her family members receive grant funding nor does she consult with any pharmaceutical or biotechnology companies. She does have strong clinical opinions based on current evidence…

Filed under:Ethics Tagged with:biasConflict of interestdisclosureEthics Forum

How Rheumatologists Can Better Partner with Social Workers

Linda Childers  |  July 18, 2019

When Liz Morasso, LCSW, facilitates a Families Living with Rheumatic Diseases support group at Children’s Hospital Los Angeles, she empathizes with the struggles and challenges of her young patients. Ms. Morasso was only 16 years old when she was diagnosed with both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She knows all too well…

Filed under:Patient PerspectivePractice Support Tagged with:Association of Rheumatology Professionals (ARP)interdisciplinarysocial worker

The Type I Interferon Pathway’s Influence in Connective Tissue Disease

Ruth Jessen Hickman, MD  |  July 18, 2019

Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:anifrolumabinterferonTULIP trials

A Month in a Colombian Hospital (with the ACR-PANLAR Exchange Program)

Nicole Bitencourt, MD  |  July 18, 2019

Colombia is a beautiful country with a rich cultural history that has made many social advances over the past decades. I was privileged to spend a month rotating with rheumatologists in San Vicente de Paul Hospital in Medellín, the City of Eternal Spring. As part of the ACR and the Pan American League of Rheuma­tology…

Filed under:Professional Topics Tagged with:ACR-PANLAR Exchange ProgramPan American League of Rheumatology Associations (PANLAR)PANLAR

ACR Volunteer Leaders Visit Capitol Hill, Lobby for 5 Issues

Ryan Basen  |  July 18, 2019

WASHINGTON, D.C.—Dozens of rheumatology leaders met with more than 100 politicos on Capitol Hill in mid-May as part of the ACR’s annual Advocacy Leadership Conference. Armed with research and advocacy training concerning a handful of important issues, rheumatologists, rheumatology interprofessional team members, government affairs specialists and others met with federal lawmakers, legislative aides and correspondents….

Filed under:ConditionsLegislation & AdvocacyOsteoarthritis and Bone DisordersResearch RheumWorkforce Tagged with:Arthritis Care & ResearchOsteoporosisprior authorizationsRheumPACstep therapyworkforce shortage

David M. Phillips / Science Source

Lyme Arthritis: Presentation, Diagnosis & Treatment

John N. Aucott, MD, & Sheila L. Arvikar, MD  |  July 18, 2019

A 52-year-old man living in greater Boston with a history of hyper­tension presented at our rheumatology clinic with bilateral knee pain and swelling. He had been in his usual state of health until four months earlier when he developed right knee pain and swelling without an incipient trauma, which did not improve with non-steroidal anti-inflammatory…

Filed under:Conditions Tagged with:Borrelia burgdorferiLyme arthritisLyme Disease

Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up

Lara C. Pullen, PhD  |  July 10, 2019

A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.

Filed under:ConditionsOther Rheumatic Conditions Tagged with:adalimumabJIAjuvenile idiopathic arthritis (JIA)Uveitis

Making Sense of Drug Pricing Legislation

From the College  |  July 2, 2019

A number of bills have been introduced in the 116th Congress to mitigate the impact of treatment and drug costs on U.S. patients. The ACR has reviewed the bills and supports those that most closely align with its positions on access to care.

Filed under:Drug UpdatesLegislation & AdvocacyProfessional Topics Tagged with:AdvocacyAmerican College of Rheumatology (ACR)drugLegislationrheumatology

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

Lara C. Pullen, PhD  |  June 25, 2019

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…

Filed under:ConditionsRheumatoid Arthritis Tagged with:adalimumabbaricitinibRheumatoid Arthritis (RA)washout

  • « Previous Page
  • 1
  • …
  • 53
  • 54
  • 55
  • 56
  • 57
  • …
  • 112
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences